We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more!

Voxeletor in Sickle Cell: doi.org/10.1056/NEJMoa1903212
Don't Mention It: doi.org/10.1200/JCO.2008.17.7238
The Raven: doi.org/10.1200/JCO.2017.76.3458
Erythropoietin Use in Cancer: doi.org/10.1200/JCO.2005.05.036
Contract Research Organizations: doi.org/10.1002/cncr.29994

Back us on Patreon! www.patreon.com/plenarysession

2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com